Melanoma — A Study of Recombinant Vaccinia Virus to Treat Malignant Melanoma
Citation(s)
A Phase I/II, Open-Label Study of JX-594 (Thymidine Kinase-deleted Vaccinia Virus Plus GM-CSF) Administered by Intratumoral Injection in Patients With Unresectable Stage 3 or Stage 4 Malignant Melanoma